Another delighted news, Researchers at ICMR-NIV collected sera from 20 recovered patients and 17 people who had received the Covaxin Dose number 2, 28 days earlier, to conduct the study.
Covaxin, which was developed in-house by Bharat Biotech in collaboration with the Indian Council of Medical Research (ICMR), is being used in adults as part of India’s ongoing COVID-19 vaccination campaign.
Source: Hindustan Times
“Despite a reduction in neutralisation titers with BBV152 vaccinee sera against B.1.351 and B.1.617.2, its neutralisation potential is well established,” the study stated, claiming that the vaccine developed by the Hyderabad-based pharmaceutical company is effective against these two variants that have caused widespread concern among doctors due to their increased severity.
The neutralization potential of the BBV152 has been already studied with the B.1, B.1.1.7, B.1.1.28.2, B.1.617.1 and found to be effective against these variants,” the study further added.
A study of this by researchers was conducted in Pune, National Institute of Virology & Bharat Biotech.
According to NDTV, the study was based on samples from 20 people who recovered from Covid and 17 others who received both doses of Covaxin. The report’s authors include ICMR chief Balram Bhargava.
The Delta variant (B.1.617.2) was discovered in India and has been linked to an increase in Covid-19 cases during the country’s second wave. The Beta variant (B.1.351) was discovered in South Africa first.
Also Read: India’s Forest Man (Jadav Payeng) Strives to Make Mexico Greener